Strategic Acquisition Cenexi was recently acquired by Fosun Pharma Group, highlighting its growth trajectory and potential for increased capital investment, which could facilitate expansion into new therapeutic areas or additional markets, offering sales opportunities in innovative drug development and manufacturing solutions.

Specialized Expertise With a strong focus on sterile and cytotoxic products, Cenexi’s advanced capabilities in manufacturing high-value, complex dosage forms present opportunities to supply specialty APIs, sterile injectables, or niche pharmaceutical formulations to pharmaceutical companies seeking reliable partners.

International Presence Operating across multiple sites in France and Belgium, Cenexi’s international footprint supports potential collaborations or supply chain integrations with companies targeting European markets, especially those looking for localized manufacturing or development services.

Innovation Collaboration Cenexi's ongoing partnership with Crossject on needle-free autoinjectors like Zeneo indicates openness to innovative delivery systems, suggesting opportunities for sales of cutting-edge medical device integration or formulation development for new drug delivery technologies.

Growth and Capacity With steady revenue growth and expanded manufacturing capacity, Cenexi is well-positioned to scale up production for new therapies or biosimilars, providing opportunities to offer contract manufacturing services for emerging markets and high-demand pharmaceutical products.